Radiopharmaceuticals

Ended Purchase Order Awarded Last action

Contract number
36C26020P0344
Awardee
Awarding agency
Obligated
$882,014

Award facts

Opportunity
Contract value 100% obligated
$882,014.09 Current and potential, with all options
Completion date 100% complete
Current and potential, with all options
Set-aside
No set-aside
Competition
Competed under SAP · 2 offers Simplified Acquisition
Pricing
Firm Fixed Price
Place of performance
Lake Mary, FL 32746, USA

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Other Administrative Action P00014 -$154,729
Funding Only Action P00013 -$358,877
Novation Agreement P00012 $0
Exercise an Option P00011 $264,989
Exercise an Option P00010 $370,689
Supplemental Agreement for work within scope P00009 -$344,442
Exercise an Option P00008 $367,093
Supplemental Agreement for work within scope P00007 -$156,610
Supplemental Agreement for work within scope P00006 -$188,957
Supplemental Agreement for work within scope P00004 -$1,735
Exercise an Option P00005 $363,535
Other Administrative Action P00003 $0
Other Administrative Action P00002 $0
Exercise an Option P00001 $361,307
Original award $359,751
Show all 15

About this award

RLS (USA) Inc., a foreign-owned radiopharmacy company headquartered in Lake Mary, Florida, was awarded a firm fixed-price purchase order valued at $882,014.09 by the Department of Veterans Affairs' Veterans Integrated Service Network (VISN) 20 on March 1, 2020. The contract, which is set aside for 8(a) small businesses under NAICS code 325412 (Pharmaceutical Preparation Manufacturing), calls for the supply of radiopharmaceuticals to support nuclear medicine diagnostic and therapeutic procedures at VA medical centers. The award originated from a pre-solicitation notice posted by the VA Puget Sound Medical Center in Seattle, Washington, with performance scheduled to conclude by August 31, 2025. RLS (USA) Inc. operates 31 radiopharmacy facilities across 18 states, enabling rapid distribution of time-sensitive medical isotopes essential for nuclear medicine imaging and treatment.

RLS (USA) Inc. serves as a critical supplier to the VA and Defense Health Agency, maintaining an extensive portfolio of radiopharmaceutical products including technetium-99m, gallium-67, fluorodeoxyglucose F-18, and specialized imaging agents. The company holds multiple significant indefinite delivery contracts with various VISN networks, including a $5.0 million IDC with VISN 17 and a $3.0 million IDC with VISN 20, establishing it as a preferred vendor across the federal healthcare enterprise. This purchase order represents one component of RLS (USA) Inc.'s substantial ongoing radiopharmaceutical supply relationship with the VA system.

Quick answers

Who was awarded contract 36C26020P0344?

36C26020P0344 was awarded to RLS (USA) Inc. by Veterans Integrated Service Network 20 (Veterans Health Administration) on March 1, 2020.

How much is contract 36C26020P0344 worth?

The government has obligated $882,014 on 36C26020P0344.

Was contract 36C26020P0344 competed?

The extent of competition for 36C26020P0344 was competed under sap. The government received 2 offers.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award